BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16675773)

  • 1. Medicare part D and decompensation.
    Park JM; Hariprasad R; Park LT
    Psychiatr Serv; 2006 May; 57(5):722-3. PubMed ID: 16675773
    [No Abstract]   [Full Text] [Related]  

  • 2. Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit.
    West JC; Wilk JE; Muszynski IL; Rae DS; Rubio-Stipec M; Alter CL; Narrow WE; Regier DA
    Am J Psychiatry; 2007 May; 164(5):789-96. PubMed ID: 17475738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnesses.
    Donohue JM
    Psychiatr Serv; 2005 Jun; 56(6):645-7. PubMed ID: 15939937
    [No Abstract]   [Full Text] [Related]  

  • 4. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients.
    West JC; Wilk JE; Rae DS; Muszynski IL; Rubio-Stipec M; Alter CL; Sanders KE; Crystal S; Regier DA
    J Clin Psychiatry; 2010 Apr; 71(4):400-10. PubMed ID: 19925748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coverage and prior authorization of psychotropic drugs under Medicare Part D.
    Huskamp HA; Stevenson DG; Donohue JM; Newhouse JP; Keating NL
    Psychiatr Serv; 2007 Mar; 58(3):308-10. PubMed ID: 17325102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mental health in the Medicare Part D drug benefit: a new regulatory model?
    Donohue J
    Health Aff (Millwood); 2006; 25(3):707-19. PubMed ID: 16684735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare.
    Morden NE; Garrison LP
    Health Aff (Millwood); 2006; 25(2):491-500. PubMed ID: 16522603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving psychiatric drug benefit management: IV. Experiences of a pharmacy advisory committee.
    Gottlieb D; Dubin WR; Ning A; Gardiner GC
    Psychiatr Serv; 2004 Nov; 55(11):1210-2. PubMed ID: 15534007
    [No Abstract]   [Full Text] [Related]  

  • 9. Managing psychotropic drug costs: will formularies work?
    Huskamp HA
    Health Aff (Millwood); 2003; 22(5):84-96. PubMed ID: 14515884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare Catastrophic Coverage Act, 1988. Part 2.
    Mehl B
    Hosp Pharm; 1989 Aug; 24(8):645-8. PubMed ID: 10303773
    [No Abstract]   [Full Text] [Related]  

  • 11. States' control of prescription drug spending: a heterogeneous approach.
    Morden NE; Sullivan SD
    Health Aff (Millwood); 2005; 24(4):1032-8. PubMed ID: 16012143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBMs and a Medicare prescription drug benefit.
    Cohen JP
    Food Drug Law J; 2000; 55(3):311-20. PubMed ID: 11824463
    [No Abstract]   [Full Text] [Related]  

  • 13. Medicare and prescription drugs.
    Iglehart JK
    N Engl J Med; 2001 Mar; 344(13):1010-5. PubMed ID: 11274630
    [No Abstract]   [Full Text] [Related]  

  • 14. The new Medicare drug benefit: much ado about little?
    Pauly MV
    LDI Issue Brief; 2004; 9(4):1-6. PubMed ID: 15035261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new Medicare bill: far-reaching effects on cancer treatment.
    Bailes JS; Coleman T
    Clin Adv Hematol Oncol; 2004 May; 2(5):292-4. PubMed ID: 16163195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Got Medicare? What people living with HIV need to know about the new Medicare drug benefit - "Part D" - starting January 1, 2006.
    Subways S
    AIDS Treat News; 2005 Sep; (415):6-8. PubMed ID: 16276606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare prescription drugs: making the new program work.
    Jaffe J
    EBRI Issue Brief; 2004 Jun; (270):1-14. PubMed ID: 15218820
    [No Abstract]   [Full Text] [Related]  

  • 18. The new Medicare prescription drug benefit: important issues for physician practices.
    Falk R; Stranne S
    J Med Pract Manage; 2005; 21(3):133-7. PubMed ID: 16471382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choosing drug of choice from restrictive formulary.
    Bender KJ
    J Clin Psychopharmacol; 1997 Jun; 17(3):145-8. PubMed ID: 9169956
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicare Part D--the product of a broken process.
    Slaughter LM
    N Engl J Med; 2006 Jun; 354(22):2314-5. PubMed ID: 16738267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.